CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lexicon Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lexicon Pharmaceuticals Inc
2445 Technology Forest Blvd, 11Th Floor
Phone: (281) 863-3000p:281 863-3000 THE WOODLANDS, TX  77381  United States Ticker: LXRXLXRX
Business Summary
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the research and development of pilavapadin, LX9851 and sotagliflozin and the commercialization of INPEFA. It is developing pilavapadin (LX9211), an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. It has completed three Phase II clinical trials evaluating the safety and tolerability of pilavapadin and its effects on diabetic peripheral neuropathic pain (DPNP) and neuropathic pain. It is developing LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic disorders and is conducting preclinical development of LX9851 in preparation for filing an investigational new drug application. It is commercializing INPEFA (sotagliflozin), an orally delivered small molecule drug, in the United States to reduce the risk of cardiovascular death, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board RaymondDebbane 70 2/22/2012 8/28/2007
Chief Executive Officer, Director MichaelExton 55 7/8/2024 7/8/2024
Senior Vice President, Chief Financial Officer Scott M.Coiante 58 1/2/2025 1/2/2025
11 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
LEXICON PHARMACEUTICALS 350 Carter Rd Princeton New Jersey United States

Business Names
Business Name
Lexicon Pharmaceuticals (New Jersey), Inc.
LXRX

General Information
Number of Employees: 103 (As of 2/28/2025)
Outstanding Shares: 363,178,000 (As of 4/3/2025)
Shareholders: 273
Stock Exchange: NASD
Federal Tax Id: 760474169
Fax Number: (281) 863-8088
Email Address: jwolford@lexgen.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 13, 2025